How Crohn's Disease Affects the Digestive Tract

A Disease That Strikes Anywhere From Mouth to Rectum

Roughly 3 million adults in the United States live with inflammatory bowel disease (IBD), and Crohn's disease accounts for nearly half of those cases, according to data from the Centers for Disease Control and Prevention. Unlike many gastrointestinal conditions that target a single organ, Crohn's can inflame any segment of the gastrointestinal (GI) tract, from the oral cavity all the way to the anus. The terminal ileum, where the small intestine meets the large intestine, is the most common site. Peak onset falls between ages 15 and 35, though diagnosis at any age is possible.

The disease was first described as a distinct clinical entity in 1932 by Dr. Burrill B. Crohn and colleagues at Mount Sinai Hospital in New York. Nearly a century later, researchers still lack a definitive cure. Treatment focuses on reducing inflammation, managing flares, and preventing complications.

How Inflammation Penetrates the Intestinal Wall

Crohn's disease produces transmural inflammation, meaning the damage extends through all layers of the bowel wall: mucosa, submucosa, muscularis, and serosa. This full-thickness involvement distinguishes it from ulcerative colitis, which remains confined to the mucosal layer.

Skip lesions are a hallmark. Diseased segments alternate with healthy tissue, creating a patchy pattern visible during colonoscopy or imaging. Granulomas, clusters of immune cells, appear in roughly 30 percent of biopsies. Chronic inflammation promotes fibrosis, narrowing the intestinal lumen and potentially causing strictures that block the passage of food.

Fistulas represent another serious complication. These abnormal tunnels can form between loops of intestine, between the bowel and bladder, or between the bowel and skin surface. They develop because the inflammation erodes through the full bowel wall and into adjacent structures.

Layers of the Intestinal Wall Affected

Symptoms That Fluctuate Between Flares and Remission

Crohn's follows a relapsing-remitting course. During active flares, patients commonly experience:

• Persistent diarrhea, sometimes bloody
• Abdominal cramping and pain, often in the lower right quadrant
• Fatigue and low-grade fever
• Unintentional weight loss from malabsorption
• Mouth sores (aphthous ulcers)
• Perianal disease including fissures, abscesses, and fistulas

Symptoms vary by location. Ileal disease produces cramping and diarrhea. Colonic involvement mimics ulcerative colitis with bloody stools. Upper GI Crohn's, rare but documented, can cause nausea and dysphagia. Extraintestinal manifestations affect up to 40 percent of patients and include joint inflammation, skin lesions like erythema nodosum, and eye conditions such as uveitis.

What Triggers the Immune System to Attack

No single cause explains Crohn's. Current evidence points to an interplay of genetics, immune dysregulation, the gut microbiome, and environmental triggers. The NOD2 gene, identified in 2001, was the first gene linked to Crohn's susceptibility. Since then, genome-wide association studies have identified over 200 genetic loci.

Smoking doubles the risk. This is a sharp contrast with ulcerative colitis, where smoking appears paradoxically protective. Other environmental factors under investigation include diet high in processed foods, antibiotic exposure during childhood, and urban living. The hygiene hypothesis suggests that reduced microbial exposure in early life may predispose the immune system to overreact to commensal gut bacteria later.

Risk Factors at a Glance

Diagnosis: Piecing Together Clinical Evidence

No single test confirms Crohn's disease. Diagnosis relies on a combination of clinical history, endoscopy, imaging, and histology. Ileocolonoscopy with biopsies is the gold standard. Capsule endoscopy can visualize the small bowel segments that a standard colonoscope cannot reach.

Blood tests reveal elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) during active inflammation. Fecal calprotectin, a stool marker, helps distinguish IBD from irritable bowel syndrome with over 90 percent sensitivity. Magnetic resonance enterography (MRE) has largely replaced barium studies for evaluating small bowel disease and detecting complications like abscesses.

• Ileocolonoscopy with biopsy: identifies location, severity, granulomas
• Fecal calprotectin: non-invasive marker of intestinal inflammation
• CRP and ESR: systemic inflammation markers
• MR enterography: evaluates small bowel and detects strictures or fistulas
• CT scan: used in emergencies for suspected perforation or abscess

Treatment Strategies From Mild to Severe

The goal is mucosal healing, not just symptom control. Aminosalicylates like mesalamine offer modest benefit for mild colonic Crohn's. Corticosteroids such as prednisone and budesonide induce remission during acute flares but carry significant long-term side effects, including bone loss and adrenal suppression. They are never maintenance drugs.

Immunomodulators, including azathioprine and methotrexate, maintain remission by suppressing immune overactivity. Biologic therapies have transformed outcomes. Infliximab, the first anti-TNF agent approved for Crohn's in 1998, blocks tumor necrosis factor alpha. Newer biologics target different pathways: vedolizumab blocks gut-specific integrin, ustekinumab inhibits interleukins 12 and 23, and risankizumab targets IL-23 selectively.

Surgery remains necessary for roughly 50 percent of patients within 10 years of diagnosis. Common procedures include strictureplasty to widen narrowed segments and resection to remove severely damaged bowel. Surgery is not curative. Recurrence at the surgical anastomosis occurs in about 70 percent of cases without prophylactic medication.

Living With a Chronic, Unpredictable Condition

Crohn's disease imposes a substantial burden. Fatigue ranks as the most disabling symptom in surveys, even during remission. Malnutrition is common because inflamed or resected bowel cannot absorb nutrients efficiently. Iron, vitamin B12, vitamin D, and zinc deficiencies require monitoring.

Psychological comorbidities affect up to 30 percent of IBD patients, with anxiety and depression occurring at higher rates than in the general population. Multidisciplinary care involving gastroenterologists, dietitians, mental health professionals, and surgeons produces the best long-term outcomes. Ongoing clinical trials continue to explore JAK inhibitors, stem cell therapy, and microbiome-based interventions. This article is for informational purposes only. Consult a qualified professional.